The FDA Public Assessment Report: A Review Package, Not a Single Document
Why Europe and Australia give you one tidy report per medicine while the US FDA gives you a folder of separate reviews, and how to read it.
What is a public assessment report?
A public assessment report (PAR) is the regulator's written explanation of why a medicine was approved. It walks through the evidence: how the drug is made, what the laboratory and animal studies showed, what the human trials demonstrated, and whether the benefits justify the risks. Because the decision is public, the reasoning behind it is public too.
The big difference between the US and the rest of the world is not whether this information is released. It is how it is packaged.
EMA, Australia and Switzerland: one consolidated document
The European Medicines Agency publishes an EPAR (European Public Assessment Report). Australia's Therapeutic Goods Administration publishes an AusPAR. Switzerland's Swissmedic likewise publishes a single Public Assessment Report (PAR) per medicine. All three are a single document per medicine, written by one team of assessors and organised into standard chapters:
- Quality (chemistry, manufacturing and controls)
- Non-clinical (pharmacology and toxicology studies)
- Clinical efficacy
- Clinical safety
- Overall benefit-risk assessment
Open the EPAR for a drug, or the AusPAR or the Swissmedic PAR, and you get the whole assessment story in one file: background, evidence, analysis, and the final benefit-risk conclusion. That is what most people picture when they hear "public assessment report".
Why the FDA is different
The US Food and Drug Administration organises review work by discipline, not by final report. The Center for Drug Evaluation and Research (CDER) assigns an application to a review team of specialists: a medical officer, a pharmacologist/toxicologist, a chemist, a clinical pharmacologist, a statistician and, where relevant, a microbiologist. Each specialist writes their own review document as they complete their part of the assessment. A senior cross-disciplinary team leader and a summary reviewer then pull the pieces together into the overall decision.
There is no step where all of that gets rewritten into one consolidated "assessment report". The individual discipline reviews are the assessment. So when FDA posts the review documents on Drugs@FDA, it posts the whole package: one document per discipline, per submission (the original application and every later supplement).
How the FDA has published its reviews over time
Before 1997: nothing public. Approval decisions were announced, but the assessment documents behind them stayed inside the agency. The Federal Register carried the fact of an approval, not the reasoning. That is why drugs approved before the late 1990s have essentially no posted review documents today. That is why the FDA PARs library only has full packages from the late 1990s onward.
1997: the legal turning point. The FDA Modernization Act (FDAMA) required the agency to make its approval packages publicly available. FDA began compiling and releasing the individual discipline reviews that made up each approval decision.
Around 2000: Drugs@FDA. The online database (accessdata.fda.gov) went live with a standardised "approval package" page per application: a table of contents linking each discipline review as a separate PDF. This is the structure the library's older documents come from.
Recently, the 2020s. FDA moved to a newer package format and began producing consolidated "Integrated Review" and "Multidisciplinary Review" documents for some new medicines, closer in spirit to the EMA's single report. Reviews are also published on a delay: the approval letter appears immediately, while the full review package is posted months later.
The practical result: an FDA "public assessment report" for a 1998 drug looks like a folder of separate PDFs, for a 2010 drug the same, and for a 2025 drug you may find a single integrated document or a fresh-format package still appearing gradually. The library collects whatever FDA has posted, whatever the era.
The anatomy of an FDA review package
A complete package typically contains some or all of these documents (these are the categories used by the FDA PARs library):
| Document | What it covers |
|---|---|
| Clinical Review | Medical evaluation of efficacy and safety in humans |
| Pharmacology/Toxicology Review | Non-clinical studies (laboratory and animal data) |
| Chemistry/CMC Review | Chemistry, manufacturing and controls (the quality of the product) |
| Clinical Pharmacology Review | How the drug moves through and acts in the body (PK/PD, bioavailability) |
| Statistical Review | Statistical evaluation of the clinical trial results |
| Summary Review | High-level summary of the whole assessment and the approval decision |
| Cross-Discipline Team Leader Review | The team leader's oversight view, weighing all disciplines |
| Microbiology-Virology Review | Microbiology assessment for anti-infectives and antivirals |
| Risk Assessment and Risk Mitigation Review | REMS (risk management and mitigation documents) |
| Multidisciplinary Review / Integrated Review | Newer consolidated formats that combine several disciplines in one document |
| Other Review | Additional regulatory review documents |
Separately, FDA posts the Approval Letter and other action letters (the official decision documents). They record what was approved but contain almost no assessment. They are not reviews, and the library keeps them out of the assessment collection.
How to read an FDA review package
Because the assessment is spread across documents, reading order matters:
- Start with the Summary Review, the shortest route to the decision and its rationale.
- Then the Cross-Discipline Team Leader Review for how the disciplines were weighed against each other.
- Then dive into the discipline reviews that interest you: Clinical for efficacy and safety, Clinical Pharmacology for dosing, Statistics for trial design and numbers, Chemistry/CMC for product quality.
- Form your own benefit-risk picture from the pieces; that is exactly how the FDA review team formed theirs.
The FDA PARs library: the package as a folder
This is why the FDA PARs library is organised the way it is. There is no single PDF to point to, so each application gets a folder containing all of its posted review documents, across the original approval and its supplements. One drug, one folder, every discipline's assessment inside, downloadable as a single ZIP. It is the closest a public library can come to "the FDA assessment report", because at the FDA, the report is the package.
Bottom line
Europe, Australia and Switzerland give you one consolidated report. The FDA gives you the raw materials, every discipline's review, and leaves the synthesis to the reader. Neither is more transparent; they are simply organised differently. Once you know the FDA package is a bundle of discipline reviews, with the summary and team-leader documents as the entry points, reading it is straightforward, and arguably more detailed than a single consolidated report could ever be.
